Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duloxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duloxetine SCHEMBL10036575 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL1200511 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3398599 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL30003730 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL30197067 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL3803 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL8291 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL2384759 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| (R)-Duloxetine SCHEMBL3901869 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F | |
| Duloxetine SCHEMBL647773 | 0.99 | SLC6A2 (0.98) | SLC6A4SLC6A2SLC6A3MLNRCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12544345-B2 | Compounds and combinations thereof for treating neurological and psychiatric conditions | Antecip Bioventures ll LLC (US) | 2026-02-10 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3319936-B1 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | HANGZHOU DAC BIOTECH CO LTD (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250339497-A1 | METHODS FOR TREATING MOOD DISORDERS BY ADMINISTERING A LEPTIN RECEPTOR AGONIST | UNIV DUISBURG ESSEN (DE) | 2025-11-06 | — | — | US | claimed |
| US-20250319043-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2025-10-16 | — | — | US | claimed |
| EP-4199904-B1 | NANO LIPID CARRIER SYSTEM FOR IMPROVING PERMEATION OF ACTIVE INGREDIENTS | LEIUTIS PHARMACEUTICALS LLP (IN) | 2025-10-01 | — | — | EP | claimed |
| EP-3536368-B1 | DRY POWDER INHALER COMPRISING A SEROTONIN RECEPTOR AGONIST AND A DIKETOPIPERAZINE FOR TREATING MIGRAINES | MANNKIND CORP (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4208466-B1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2025-06-11 | — | — | EP | claimed |
| US-20230248720-A1 | Long Acting Injectable Formulations | ABON PHARMACEUTICALS, LLC | 2023-08-10 | — | — | US | claimed |
| CN-116134641-A | Rechargeable metal halide cell with embedded anode | 国际商业机器公司 | 2023-05-16 | — | — | CN | claimed |
| EP-3319613-B1 | USE OF AMINE CARBOXYBORANES AS THERAPEUTIC DELIVERY OF CARBON MONOXIDE AND AS GENERAL DRUG DELIVERY SYSTEM IN THE PRESENCE OF REACTIVE OXYGEN SPECIES | UNIV NEW YORK STATE RES FOUND (US) | 2023-02-22 | — | — | EP | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3454853-B1 | TREATMENT OF ALCOHOLISM AND DEPRESSION USING IBUDILAST | MEDICINOVA INC (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| CN-114377007-A | Duloxetine and SEP-363856 combined pharmaceutical composition for treating depression | 江苏海洋大学 | 2022-04-22 | — | — | CN | claimed |
| WO-2022054927-A1 | COMPOSITION FOR AUTOPHAGY ACTIVATION | 国立大学法人大阪大学 | 2022-03-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544345-B2 | Compounds and combinations thereof for treating neurological and psychiatric conditions | CYP2D6, SLC6A4, COMT | SLC6A4 2/4885SLC6A2 8/4885SLC6A3 10/4885 |
| US-20250319043-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | CYP2D6, GRIN3A, GRIN2B | SLC6A4 30/4885SLC6A2 58/4885SLC6A3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.